Qiming Venture Partners

Qiming Venture Partners, established in 2006, is a leading China-based venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds totaling $9.5 billion, focusing on early and growth-stage investments in the Technology and Consumer (T&C) and Healthcare industries. With a strong track record, over 200 portfolio companies have achieved exits, and over 70 have become unicorns or super unicorns. Qiming Venture Partners USA, founded in 2017, is its affiliate in Cambridge, Massachusetts, specializing in healthcare, therapeutics, and digital health investments. The firm is known for its deep technical expertise, hands-on operational support, and thought leadership in the venture capital industry.

Zhang Ao

Executive Director

Artavazd Arumov Ph.D

Principal

Cyrus Chan

Associate

Nan Chen

Principal

David Chu

Partner

Phil DiGiacomo

Principal

Anna French

Managing Partner

Yuxin Fu

Vice President

Jinda Gao

Principal

Kuantai Yeh

Partner

Robert Headley

Partner

Maykin Ho

Venture Partner

William Hu

Managing Partner

Duane Kuang

Co-Founder and Managing Partner

Nisa Leung

Managing Partner

Dingzheng Li

Vice President

Jing Liu

Vice President

Chang Liu

Associate

Bin Liu

Vice President

Biao Lu

Associate

Shuo Mao

Principal

Will McConnell

Principal

Gary Rieschel

Founder and Managing Partner

James Shen

Venture Partner

Motao Sun

Vice President

Amy Tang

Venture Partner

Yi Tang

Principal

Shiyu Wang

Partner

Rachel Wang

Venture Partner

James Wang

Venture Partner

Jing Wu

Partner

Gillian Xu

RMB funds CFO

Peter (Ming) Yin

Principal, Cleantech

Janet Yu

Partner

Oscar Zhang

Principal

Yafeng Zhou

Associate

Alex Zhou

Partner

Zhiyuan Zhou

Associate

Zhifeng Zhou

Managing Partner

Jing-Shan Hu Ph.D

Venture Partner of Healthcare

Phillip DiGiacomo Ph.D

Principal

1061 past transactions

iflybuds

Seed Round in 2025
Vision Intelligence is a AI smart hardware company that manufactures and sells interactive intelligence based electronic consumer products.

TARS

Angel Round in 2025
Zhihang Zhong is a prominent researcher in the field of artificial intelligence, particularly known for his work on integrating spatial perception and reasoning into AI systems.

Force Inspiration

Angel Round in 2025
Force Inspiration is a start-up focusing on embodied intelligence technology. The company mainly engages in technology development, technical consulting, software development, basic artificial intelligence software development, information system integration services, intelligent robot research and development and sales, and industrial robot manufacturing and sales.

Eco Polymer

Series B in 2025
Eco Polymer specializes in research and the production of medical catheters and membrane materials.

Weimei Health

Series A in 2025
Weimei Health is a provider of smart solutions for medical information technology

Singular Medical

Series C in 2025
Singular Medical is a technology company focused on the research, development, and industrialization of cardiac rhythm management (CRM) products. The company designs and develops a comprehensive range of high-quality medical devices, including implantable cardioverter defibrillators, pacemakers, and implantable cardiac monitors. Singular Medical aims to provide reliable and professional medical equipment that addresses the needs of a large population of cardiac patients, offering solutions that span from initial detection to ongoing follow-up care.

TOPI Imaging Technology

Series E in 2025
TOPI Imaging Technology is a medical device firm providing OCT retinal diagnostic system and sweep optical biometer.

Pulnovo Medical

Series C in 2025
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.

Video Rebirth

Angel Round in 2025
Video Rebirth Limited is a private limited company that is established with shares.

DH-Robotics

Venture Round in 2025
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.

Nanos Medical

Venture Round in 2025
Nanos Medical specializes in the research, development, manufacturing, and sales of disposable medical devices, primarily targeting the cardiovascular and ear, nose, and throat (ENT) fields. The company offers a range of innovative products, including sinus balloon catheters, eustachian tube balloons, disposable nasopharyngeal airways, nasolacrimal balloons, and drug-eluting stents for sinus applications. Through its advanced medical devices, Nanos Medical aims to enhance treatment options for hospitals and patients, contributing to improved healthcare outcomes.

Vivatides Therapeutics

Series C in 2025
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.

Stairway Medical

Series B in 2025
Stairway Medical is a ladder of human progress and evolution stairs up for human health. The technology and products will be applicable to medical scenarios such as human function restoration, disease treatment, and functional enhancement, as well as related scientific research work.

Makera

Angel Round in 2025
Makera is essentially creating a maker's dream CNC machine; we use it every day for various projects and enjoy the experience, and we hope you will too.

Auron Therapeutics

Series B in 2025
Auron Therapeutics is a biotechnology company based in Wellesley, Massachusetts, dedicated to developing innovative therapies for cancer. Founded in 2018, the company aims to transform the treatment paradigm by shifting from traditional cell-killing approaches to differentiation therapy, which seeks to convert malignant cells into normal functioning cells. This strategy reactivates the body's inherent cellular programs to promote tumor maturation and restore normal tissue. Auron Therapeutics utilizes advanced platforms that integrate large omic datasets with high-throughput flow cytometry, enabling the rapid identification and validation of multiple therapeutic targets and drugs using primary human patient samples. Through its research, the company aspires to address unmet medical needs in oncology and provide life-saving treatments for cancer patients.

Baoling Bio

Series B in 2025
Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia.

MiGuo AI

Angel Round in 2025
Miguo AI enhances artificial intelligence in various industries and transforms visual content creation.

Xi'an Dunbo Medical Equipment

Series A in 2025
Xi'an Dunbo Medical Equipment focuses on the research, development, and production of AI medical devices. The products currently under development are cardiac pacemakers and brain pacemakers, Cardiac defibrillators. Self-developed products include chips, hardware circuits, software application systems, and structural materials.

Xinzeyuan

Series B in 2025
Xinzeyuan Medical is a manufacturer specializing in precision components and consumables for medical endoscopes. The company focuses on producing minimally invasive surgical instruments and various medical consumables, aimed at enhancing the safety and efficiency of surgical treatments for medical professionals. By delivering high-quality products, Xinzeyuan Medical plays a vital role in supporting healthcare providers and improving patient outcomes.

Iongen Therepeutics

Seed Round in 2025
Iongen Therepeutics is an innovative drug research and development company focusing on pain treatment.

Umoja Biopharma

Series C in 2025
Umoja Biopharma specializes in innovative immunotherapy aimed at transforming cancer treatment and enhancing patient quality of life. The company focuses on reprogramming T cells within the patient's body to effectively target cancer, including solid tumors and hematological cancers that often have poor responses to conventional therapies. Its proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens tailored to various stages of cancer, enabling medical practitioners to directly and safely attack cancer cells. By harnessing the body's immune response, Umoja Biopharma seeks to improve overall patient outcomes and provide more effective treatment options for those affected by cancer.

Cornerstone Robotics

Series C in 2025
Cornerstone Robotics is dedicated to enhancing the accessibility of advanced medical services in China through the development of medical robotic devices. The company is focused on creating a safe and efficient surgical robotics platform aimed at improving the accuracy and efficiency of surgical operations. By prioritizing research and development, Cornerstone Robotics enables physicians to perform surgeries with greater precision, ultimately contributing to better patient outcomes in the healthcare sector.

Windward Bio

Series A in 2025
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Leyden Labs

Series B in 2025
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

AusperBio

Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.

StepStar

Series B in 2024
The goal of Stepstar is to "Ten Times the Possibility of Everyone" through Intelligent Step. Step Star firmly creates its own super model and actively uses important resources like

Zhipu AI

Venture Round in 2024
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.

Tenpoint Therapeutics

Venture Round in 2024
Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Soda Health

Series B in 2024
Soda Health is a healthcare technology company founded in 2021 and based in Chicago, Illinois. The company focuses on addressing health inequities by leveraging social determinants of health. It offers a technology platform designed to assist individuals in identifying, accessing, and funding the resources necessary for a healthy life. By providing a system for administering and reimbursing personalized benefits, Soda Health enables customers to effectively bridge the gap between medical claims and retail payments, ultimately promoting better health outcomes.

Bioheng

Series C in 2024
BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

iMile

Series C in 2024
iMile is a logistics and courier services provider operating across the Middle East, specializing in solutions for the e-commerce sector. The company is notable for being the first courier service to effectively address Cash On Delivery (COD) needs, offering a suite of services that includes cash-on-delivery options with tracking, real-time online shipment tracking, and comprehensive customer support available through various channels. iMile also facilitates international transport and maintains overseas warehouses, ensuring efficient last-mile delivery. Its innovative platform enables clients to manage cross-border deliveries seamlessly, enhancing the overall logistics experience.

Tupos Therapeutics

Seed Round in 2024
The company is currently operating in Stealth Mode.

Duet

Series C in 2024
Duet is a dating application helps you find meaningful relationships based on shared interests and experiences.

Dearer Medical

Venture Round in 2024
Dearer Medical is a medical device company based in China that specializes in the development, production, and sales of eye-related products, particularly contact lenses. The company emphasizes research and development to create both practical and fashionable color contact lenses, catering to a diverse customer base. Through its innovative approach, Dearer Medical aims to enhance the user experience while addressing the aesthetic and functional needs of contact lens wearers.

Tianhu Technology

Series A in 2024
Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

Matwings Technology

Series A in 2024
Matwings Technology is a biotechnology company that specializes in the design of functionally optimized proteins using advanced evolutionary methods. It focuses on the development of innovative drug molecular design through computational chemistry and artificial intelligence. Matwings collaborates with major pharmaceutical companies to conduct early-stage research and development of drugs targeting complex clinical challenges. The company's goal is to achieve breakthroughs in drug targets that are typically difficult to formulate, emphasizing the clinical value of its innovations.

Bioyond Tech

Series A in 2024
Bioyond Tech utilizes robotics and artificial intelligence technology to provide a new generation of modular products and automation solutions for the life sciences sector.

IntoCare

Series D in 2024
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.

XellSmart

Series B in 2024
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

LaNova Medicines

Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Tachem

Series B in 2024
Tachem is a biotechnology company that specializes in the research, development, production, and distribution of products from the protected amino acid series.

Bytelumio

Series A in 2024
Bytelumio creates advanced all-optical networks that deliver high-speed connections of 800G and 1.6T for data centers.

Original Point

Series C in 2024
Original Point focuses on the development of CNC systems with five-axis and multi-axis linkage capabilities.

Hope Medicine

Series B in 2024
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Longbio Pharma

Series B in 2024
Longbio Pharma is a biotechnology company focused on developing treatments for patients with complement and allergy diseases, particularly in the autoimmune sector. The company aims to provide affordable and high-quality biomedicines to both domestic and international markets. By leveraging its innovative platform, Longbio Pharma seeks to enhance treatment options for healthcare professionals, ultimately improving patient outcomes in the field of allergy and complement-related illnesses.

Candid Therapeutics

Series A in 2024
Candid Therapeutics is a biotechnology company specializing in the development of innovative therapies for immunological disorders. The company's primary focus is on creating novel, user-friendly treatments for autoimmune diseases. Their core technology involves advanced T-cell engager antibodies, which precisely redirect T-cells to selectively eliminate autoreactive B-cells, aiming to deliver transformative efficacy and improved therapeutic outcomes for patients.

Epigenic Therapeutics

Series A in 2024
Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Zhipu AI

Series D in 2024
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.

Infinigence

Series A in 2024
Infinigence is dedicated to providing AGI computing power solutions based on its large model energy efficiency optimization tools, with the goal of resolving the challenge of efficient and unified deployment of large model algorithms to large computing power chips.

Shanghai Mufan Power

Series B in 2024
Mufan Power is a high-tech enterprise specializing in turbomachinery, focused on developing zero-carbon hydrogen power generation technologies. The company manufactures hydrogen gas turbines designed for various applications, including distributed energy systems, data centers, rail transit, marine power, vehicle propulsion, and energy storage peak shaving. Mufan Power also offers technical consultation and engineering services related to gas turbines, steam turbines, and other turbomachinery, having contributed to the design and development of significant national heavy equipment in China.

SPEEDIANCE

Series B in 2024
Speediance focuses on the development of smart self-service gym equipment tailored for at-home strength training. The company offers innovative fitness equipment that integrates an online platform, providing users with training guidance and access to various courses related to strength training. This approach allows individuals to connect with a broader workout community, enhancing their home workout experiences and promoting effective exercise routines.

Pelliot

Series B in 2024
Pelliot is an outdoor sports brand specializing in innovative design and R&D of outdoor functions, offering PT-CHINA natural technology platform and product lines for performance, mountain, classic, and training.

Guangjing Energy

Series A in 2024
Guangjing Energy specializes in the R&D and mass production of durable, large-area perovskite solar cell modules. They develops perovskite film printing technology with independent intellectual property rights and realized the preparation of large-area perovskite components.

Zhongyi Rehabilitation

Seed Round in 2024
Zhongyi Rehabilitation is a provider of rehabilitation products and services that focuses on the operation of chain rehabilitation centers to provide patients with one-stop professional rehabilitation needs and solutions.

TandemAI

Series C in 2024
TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution.

FXiaoKe

Venture Round in 2024
FXiaoKe is a Beijing-based company that specializes in cloud-based sales management solutions for Chinese businesses, particularly targeting small and medium-sized enterprises. Established in December 2011 by Luo Xu, the company provides a comprehensive platform that integrates field operation management, distribution chain management, and customer relationship management. FXiaoKe's software enables businesses to enhance their sales processes through a social interaction platform that merges features of dynamic customer relationship management with capabilities akin to enterprise WeChat. The platform supports collaboration across various sectors, including high-tech industries, corporate services, fast-moving consumer goods, agriculture, and large-scale manufacturing, facilitating efficient marketing, sales, and service operations. Additionally, FXiaoKe offers online office automation services that allow seamless information sharing between personal computers and smartphones, further enhancing customer management.

SinoUnited Health

Series D in 2024
SinoUnited Health is a medical center based in Shanghai, China, specializing in sports medicine, physical therapy, pain management, orthopaedics, and neurology services. Established in 2004, the center offers a comprehensive range of treatments, including services for foot and ankle issues, acupuncture, chronic pain management, movement disorders, migraines, tremors, electromyography, balance training, and post-stroke care. The facility is designed to provide a comfortable environment that meets international standards, ensuring a high-quality experience for patients. SinoUnited Health has built a strong reputation for delivering reliable diagnoses and effective treatment outcomes, reinforcing its commitment to enhancing patient satisfaction and well-being within the community.

Chenzhang Biotechnology

Seed Round in 2024
Chenzhang Bio is a biotechnology developer specializing in stem cell storage and treatment technology. focusing on stem cell storage and treatment technologies, company's research and commercialization, enhancing its R&D team and promoting clinical application of stem cell treatment technology

Dr.Clear Aligner

Series A in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.

CSR Biotech

Series A in 2024
CSR Biotech is a biological research company that specializes in super-resolution imaging technologies for living cells. The company focuses on the research, development, and manufacturing of advanced imaging instruments, providing a range of services such as customized cell sample generation, high-throughput detection, and imaging studies. Additionally, CSR Biotech offers image post-processing and quantitative analysis, along with high-dimensional spatio-temporal data visualization. These services are designed to support bio researchers in discovering new disease biomarkers and innovative drug targets, thereby enhancing the capabilities of scientific exploration in the field of biotechnology.

Outpace Bio

Series B in 2024
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.

LTZ Therapeutics

Series A in 2024
LTZ Therapeutics is engaged in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. The company employs reverse translational science and tumor biology, integrating these approaches with machine learning to advance its immunotherapy solutions. This strategy enables LTZ Therapeutics to create novel cancer treatments that address significant unmet clinical needs, ultimately striving to improve patient outcomes in the field of oncology.

Engitist

Series B in 2024
Engitist is a company based in Suzhou, China, that specializes in the research, manufacture, and sale of semiconductor optical measurement and testing equipment. Founded in 2018, Engitist offers a range of products including microscopic film measurement, optical defect detection, and optical linewidth measurement. The equipment is designed to provide high accuracy and reliability, enabling semiconductor manufacturers to effectively monitor product quality and enhance the sophistication of their semiconductor products. Engitist serves a global clientele, delivering high-quality solutions tailored to the needs of the semiconductor industry.

SonoSilicon

Angel Round in 2024
SonoSilicon researches on medical-grade micro-on-chip ultrasound systems and chip design and promotes the medical device industry.

LaNova Medicines

Series C in 2024
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.

Alpha Biopharma

Series B in 2024
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.

DK Medtech

Series E in 2024
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.

Simaixu Biotechnology

Angel Round in 2024
Simaixu Biotechnology is a biopharmaceutical firm that develop small molecule drugs for cancer, and chronic diseases with new technologies

Novamab

Series B in 2024
Novamab is engaged in the research and development of innovative nanobody pharmaceuticals aimed at improving treatment options in the pharmaceutical industry. With a team experienced in nanobody research, the company has developed multiple specialized platforms, including an inhaled macromolecular drug platform, an albumin nanobody long-acting platform, and a nanobody double-antibody platform. These innovations leverage the unique advantages of nanobodies to create novel drug delivery methods, such as sprays and eye drops, addressing significant challenges in the management of chronic diseases. Novamab's research focuses on critical medical areas, including tumors, autoimmune disorders, and cardiovascular diseases, ultimately enabling healthcare professionals to enhance patient outcomes.

Thorough Future

Series A in 2024
Thorough Future specializes in the integration of advanced technology within the medical sector, focusing on enhancing diagnostic services in clinical medicine. The company leverages artificial intelligence and big data to offer intelligent diagnosis and predictive services for pathology images. This innovative approach aims to improve diagnostic accuracy and efficiency, particularly for cancer patients, by providing personalized treatment recommendations. Through its commitment to integrating cutting-edge technology into healthcare, Thorough Future seeks to transform the way medical diagnoses are conducted and treatments are tailored.

Dezhen Technology

Series C in 2024
Dezhen Technology provides solutions for medical institutions to help hospitals develop clinical, and scientific research management. Dezhen Technology is headquartered in Hongkou, China.

Horizone Technologies

Series A in 2024
Horizone Technologies is membrane materials and excellent filtration solutions manufacturer focusing on the R&D and production

Yanshengchao

Angel Round in 2024
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China

Shengshu Technology

Venture Round in 2024
Shengshu Technology specializes in generative artificial intelligence infrastructure, focusing on the development of multi-modal large-scale models that integrate various forms of information, including text, images, videos, and 3D content. The company offers a sophisticated 3D image generator that employs Multi-Modal Diffusion models based on transformers. This technology allows clients in design, game production, and post-production to create images tailored to their specific requirements regarding composition, style, and precision.

Yidao Biotechnology

Series C in 2024
Yidao Biotechnology research and develops vaccines and biomedical products. It focuses on the research and development of a variety of vaccines such as recombinant protein antigen vaccine, new virus vector vaccine, messenger RNA vaccine, and vaccine adjuvant platforms, providing vaccines to meet the needs of human health in both domestic and international markets. The Suzhou, Jiangsu-based biotech company was established in 2017.

Brise Pharma

Seed Round in 2024
Brise Pharma is a biopharmaceutical company dedicated to developing innovative drugs aimed at treating pain. The company focuses on creating highly differentiated analgesic treatments for various debilitating pain conditions, particularly targeting migraine, neuropathic, and musculoskeletal pain. By addressing significant unmet needs in pain management, Brise Pharma aims to enable healthcare providers to offer safe, effective, and accessible pain relief solutions for patients worldwide who suffer from poorly managed pain conditions.

GenEditBio

Seed Round in 2024
GenEditBio is a biotechnology company that focuses on developing gene editing drugs to address unmet medical needs associated with genetic diseases. The company specializes in innovative research and the advancement of in vivo gene editing tools, along with related delivery systems. By providing curative solutions, GenEditBio aims to improve treatment options for patients suffering from genetic disorders.

Jiakekangnuo Bio

Angel Round in 2024
Jiakekangnuo Bio focuse on technology, promote industrial incubation through strategic investment, and achieves commercialization.

CureGenetics

Series B in 2024
CureGenetics is a biotechnology company focused on developing innovative medicines and molecular diagnostics aimed at treating cancers and genetic diseases. The company specializes in research and development of gene editing technologies and delivery platforms, which are designed to provide advanced treatment solutions. By leveraging cutting-edge applications, CureGenetics seeks to address the challenges posed by these complex medical conditions through next-generation therapeutic approaches.

Emulate

Series F in 2024
Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

Chunyu Yisheng

Venture Round in 2024
Chunyu Yisheng is a mobile application that enables physicians and their patients to communicate with each other. The application provides physicians with access to their patients’ medical records. Furthermore, it enables the patients to communicate and schedule appointments with the doctors. In addition, it offers reservation line treatment services to its users. Chunyu Yisheng was launched in 2011 by Rui Zhang and is based in Beijing.

Zhipu AI

Series B in 2024
Zhipu AI is a data company focused on developing an AI-based large model platform that offers API services tailored to various customer needs. The company provides a range of smart application products, including the scientific and technological information analysis engine "AMiner" and AI cognitive engines such as CodeGeeX and CogView. These tools are designed to help users automate and optimize digital tasks, thereby reducing the required manual labor. Zhipu AI's advanced applications are built on its General Language Model (GLM) series, capable of handling tasks in both Chinese and English, making its offerings versatile and applicable across different linguistic contexts.

Shengshu Technology

Seed Round in 2024
Shengshu Technology specializes in generative artificial intelligence infrastructure, focusing on the development of multi-modal large-scale models that integrate various forms of information, including text, images, videos, and 3D content. The company offers a sophisticated 3D image generator that employs Multi-Modal Diffusion models based on transformers. This technology allows clients in design, game production, and post-production to create images tailored to their specific requirements regarding composition, style, and precision.

Pinnacle Medicines

Series A in 2024
Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.

DH-Robotics

Series C in 2024
DH Robotics Technology Co., Ltd., founded in 2016 and based in China, specializes in the research and development of robotic hands and industrial robots. The company focuses on creating electric gripping jaws intended to enhance intelligent manufacturing processes. Its products are designed to be stable, secure, and easily integrated, catering to the needs of advanced manufacturing and lean production. By developing cost-effective solutions, DH Robotics aims to support flexible and intelligent demands within the manufacturing sector.

Alamar Biosciences

Series C in 2024
Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

Dr.Clear Aligner

Series F in 2024
Dr.Clear is an oral invisible orthodontic solution service provider that specializes in offering safe and comfortable digital solutions for face development management and invisible dental correction for children and adolescents.

Hope Medicine

Series B in 2024
Hope Medicine focuses on researching, developing, and commercializing innovative biopharmaceuticals aimed at enhancing the quality of life for patients with various prevalent diseases. The company specializes in translational medicine, utilizing insights from global research initiatives to create monoclonal antibodies, protein drugs, and other therapeutic options targeting endocrine, cardiovascular, and metabolic disorders. By addressing the needs of underserved patient populations, Hope Medicine strives to improve health outcomes and provide access to effective and affordable treatments.

Jasper Therapeutics

Post in 2024
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, focused on developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. The company aims to create safer conditioning agents that enable broader use of curative therapies, particularly through its novel engineered hematopoietic stem cells platform. Its lead compound, JSP191, is a humanized monoclonal antibody currently in clinical development. This agent functions as a conditioning treatment by targeting and clearing hematopoietic stem cells from bone marrow, facilitating successful stem cell transplants. By addressing the limitations of transplant grafts, Jasper Therapeutics seeks to increase the number of patients who can benefit from both allogeneic and autologous gene-edited hematopoietic stem cell therapies.

Silicon Yi Technology

Venture Round in 2024
Silicon Yi Technology is a biotech firm specializing in RNA nanopesticide research and development designed to target pests and diseases.

Ruining Bio

Series B in 2024
Ruining Bio provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolization, and anti-tumor drugs. Ruining Bio brings together various professionals in materials, chemistry, biomedical engineering, and clinical medicine.

Magair Chemical

Series A in 2024
Magair Chemical is a chemical synthesis CRO that was founded by Magera Technology. It is committed to using automated and intelligent platforms to provide new drug R&D customers with a new generation of chemical synthesis CRO services, significantly shortening the delivery of chemical synthesis links in the new drug R&D cycle, and significantly reducing the costs associated with chemical synthesis, removing pharmaceutical synthesis's current reliance on manual operations.

Supermag

Series A in 2024
Suzhou Supermag Intelligent Technology Co., Ltd. (hereinafter referred to as Suci Technology) is committed to the research and development, production and sales of maglev high-speed motors. With the design authorization of magnetic levitation compressors, magnetic levitation blowers, magnetic levitation pumps, etc., it provides core components such as magnetic levitation motors, magnetic levitation bearings, magnetic levitation controllers, and displacement sensors.

DeBank

Series B in 2024
DeBank is a cryptocurrency wallet designed to facilitate access to decentralized finance (DeFi) services, enabling users to manage and track their DeFi investments effectively. The platform supports over 800 DeFi protocols across more than 15 blockchains, including Ethereum and Binance Smart Chain. Users can monitor their asset portfolios, compare interest rates, and analyze risks associated with their investments. DeBank also offers features for token swapping and discovering new investment opportunities through detailed real-time data, allowing users to gain insights into their financial activities and optimize their returns in the DeFi space.

Xiaoe Tech

Series D in 2024
Xiaoe Tech is a technology service provider specializing in new education solutions. The company offers a range of products, including knowledge payment SaaS, new education SaaS, and enterprise training tools, alongside PaaS cloud services and content distribution solutions. Xiaoe Tech supports content entrepreneurs and educational institutions by providing essential resources such as tools, data, traffic, and talent needed to enhance their operations. Their services facilitate brand communication, traffic growth, classroom teaching, and student management, ultimately aiming to streamline business monetization in the education sector. The company’s focus is on helping clients build and manage their online knowledge platforms effectively, thereby promoting a closed-loop ecosystem for knowledge dissemination.

PRCXI Biotechnology

Seed Round in 2024
PRCXI Biotechnology is a biotech company that provides bioinformatics and automation solutions for life science and the manufacturing of analytical instruments.

Swap

Series A in 2024
Swap is a company that makes a battery interchange system that is designed to replace the traditional charging process for electric motors. The company offers an energy switching system comprised of both energy stations and handmade batteries that can be used with the assistance of a mobile application, allowing users to supply speed and timeliness to bike riders at a low cost. The company aims to support the nation's zero-emission goal by providing the revolutionized charging infrastructure

ACXEL

Series A in 2024
ACXEL Tech specializes in large area electronics, focusing on digital microfluidic cell manipulation platforms that enhance drug discovery and biological research. By transforming active pixels into precise engines, ACXEL's technology enables the rapid transport of liquid droplets, facilitating complex experimental procedures at the single-cell level. This innovative approach supports various applications, including cell line development, cell therapy, synthetic biology, and antibody therapy. The platform's high throughput and low-cost design provide clients with the ability to increase productivity and efficiency in their research efforts across chemistry, biology, and medical technology.

Leapstack

Series C in 2023
Leapstack is an insurance technology company based in Shanghai, with additional offices in Beijing and Nanjing. Founded in February 2016, it focuses on developing big data artificial intelligence solutions tailored for commercial insurance companies and social security management agencies. The company's platform enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, anti-fraud measures, and compliance identification. By addressing inefficiencies in the industry, Leapstack aims to improve operational effectiveness and provide comprehensive data analysis and management tools for its clients.

Yibai Health

Venture Round in 2023
Yibai Health is a clinical research medical group that builds clinical trial centers for hospitals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.